Perspectives
Realising the promise of cell and gene therapies in Asia Pacific
Four imperatives for commercial delivery
The next generation of cell and gene therapies (CGTs) holds tremendous potential for therapeutic benefits. To realise this promise, stakeholders need to come together to optimise value chain and recalibrate commercial delivery.
The next generation of cell and gene therapies (CGTs) holds tremendous potential for therapeutic benefits. Based on Deloitte's vast experience in the commercial launch of CGT products, we discuss how stakeholders can come together to optimise value chain and recalibrate commercial delivery.